The Latest Breaking News on Pharma

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

While Palatin Technologies (PTN) has faced challenges with declining share price, negative analyst projections, and limited profitability, it's worth noting the consistent growth in the broader biotech industry. Thus, investors could find more stable returns in robust biotech stocks Protalix BioTherapeutics (PLX), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) instead. Read…

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

GSK-controlled company works on developing patient-administered treatment by end of the decade

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

While pharmacies say they can still fill most prescriptions for amoxicillin, the most-prescribed drug in the country, the shortage could worsen when the viral season hits this winter, experts say.

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.